US/UK/Canada

Share

About Us

Cantargia AB (publ), reg.no. 556791-6019, is a biotech company which is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at http://www.cantargia.com.

Contacts

  • Cantargia AB
    Scheelevägen 27 223 63 Lund
    +46 (0)46 2756260
    http://www.cantargia.com
    • Pick a time period -
    Tags ( Active)

    Cantargia to host R&D Day on new clinical results of nadunolimab in pancreatic cancer on April 24, 2023

    Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day focusing on new clinical results and biomarker data for its lead asset, the IL1RAP-binding antibody nadunolimab (CAN04), in pancreatic cancer (PDAC) patients, following presentation of these results at the AACR Annual Meeting 2023 (AACR 2023). The R&D Day will be hosted by Cantargia management and Prof. Eric Van Cutsem, principal investigator in the CANFOUR trial.Cantargia recently announced new results from the phase I/IIa clinical trial CANFOUR, evaluating nadunolimab in combination with chemotherapy

    Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer

    Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that two abstracts on its lead asset, the antibody nadunolimab (CAN04), have been selected for poster presentation at the AACR Annual Meeting 2023 (AACR 2023). A key finding is that pancreatic cancer (PDAC) patients with high tumor levels of IL1RAP, the target of nadunolimab, benefit most from nadunolimab combined with chemotherapy. This further strengthens previously reported signs of clinical efficacy of nadunolimab in PDAC. The abstract disclosing these and additional biomarker data has now been published, as well as a second

    Cantargia treats first triple-negative breast cancer patient in randomized phase II part of TRIFOUR trial

    Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that, following positive results in the lead-in phase of the clinical phase Ib/II trial TRIFOUR, the first triple-negative breast cancer (TNBC) patient has initiated treatment with the IL1RAP-binding antibody nadunolimab (CAN04) and chemotherapy in the phase II randomized part of the trial. Up to 98 patients may be included in this part and the next milestone, an interim futility analysis of 28 patients, is estimated in Q4 2023.“We are proud to have started Cantargia’s first randomized trial with nadunolimab, in patients with

    Cantargia publishes full year report for 2022

    Cantargia AB’s (”Cantargia”) full year report for 2022 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the fourth quarter · A milestone was reached in the CAPAFOUR and CESTAFOUR trials when enough patients had been enrolled to end recruitment. Cantargia announced that clinical development of nadunolimab will focus on randomized studies. The CIRIFOUR trial was also stopped. · New results showing the effect of nadunolimab on various tumor-promoting molecules were presented at the SITC conference. · New positive

    Cantargia advances TRIFOUR trial to randomized stage following promising early safety and efficacy of nadunolimab in triple-negative breast cancer

    Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported favorable safety and promising early signs of efficacy following an initial analysis of the phase Ib part of the clinical trial TRIFOUR. In collaboration with the Spanish Breast Cancer Group (GEICAM), this trial investigates the IL1RAP-binding antibody nadunolimab (CAN04) in combination with chemotherapy for treatment of triple-negative breast cancer (TNBC). In 12 patients treated long enough for evaluation, the response rate was well above previously reported data for chemotherapy alone. The trial is now expanding into the

    Invitation to presentation of Cantargia’s Year-end report of 2022 on February 23 at 3.00 p.m. CET

    Cantargia AB will publish the company’s Year-end report for January-December 2022 on Thursday, February 23, 2023, at 08:30 a.m. CET.In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on February 23, at 3:00 p.m. CET, where Göran Forsberg, CEO, and Bengt Jöndell, CFO, will present Cantargia and comment on the Year-end report for January-December 2022, followed by a Q&A-session. If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions. Webcast: https:/

    Cantargia announces appointment of Patrik Renblad as Chief Financial Officer

    Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA), a clinical-stage biotech company focused on antibody-based therapies targeting IL1RAP for cancer and inflammatory diseases, today announced it has appointed Patrik Renblad as its new Chief Financial Officer (CFO). Mr Renblad will assume this role by August 2023, at the latest.“I am delighted to welcome Patrik Renblad as Cantargia’s new CFO. Patrik brings a wealth of experience gained from an international career with leading positions in both pharma and biotech, which will be important to Cantargia in the next stage of the company’s

    Cantargia successfully concludes toxicity study with CAN10 antibody ahead of phase I clinical trial application

    Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced that the Good Laboratory Practice (GLP) toxicity study for its anti-inflammatory IL1RAP-binding antibody CAN10 has been concluded. Data from the study show that CAN10 was well tolerated when administered over six weeks. Cantargia plans to initiate the phase I clinical trial for CAN10 during the first half of 2023.In the present GLP toxicity study, CAN10 was given intravenously once weekly for six weeks at doses up to 50 mg/kg, which is well above the intended clinical dose levels. CAN10 was also administered subcutaneously at

    Nomination Committee appointed ahead of 2023 Annual General Meeting

    Cantargia AB (publ) hereby provides notification that the Nomination Committee has been appointed ahead of the 2023 Annual General Meeting, and consists of, Jan Särlvik (Fjärde AP-fonden), Mikael Wiberg (Alecta Pensionsförsäkring, Ömsesidigt), Mats Larsson (Första AP-fonden) and Magnus Persson (Chairman of the Board). The Nomination Committee has been appointed in accordance with the guidelines established at the 2022 Annual General Meeting.As of 30 September 2022, the Nomination Committee represents a total of 22,5 per cent of shares in Cantargia. The Nomination Committee is responsible

    Cantargia publishes interim report for third quarter 2022

    Cantargia AB’s (”Cantargia”) interim report for the period January until September 2022 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports. Significant events in the third quarter · A significantly oversubscribed rights issue was completed, raising approximately SEK 250 million before deduction of transaction costs. · New preclinical data were presented for both nadunolimab and CAN10. For nadunolimab, results were reported showing anti-tumor efficacy in combination with chemotherapy, as well as effects on stromal cells in pancreatic cancer

    Cantargia’s CAN10 demonstrates positive activity in systemic sclerosis models in new data presented at ACR Convergence 2022

    Strongly supports therapeutic potential in one of CAN10’s lead indications Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data demonstrating positive effects of the IL1RAP-binding antibody CAN10 in three different in vivo models of systemic sclerosis, a lead indication for the drug candidate. Across the models, which mimic difficult-to-treat forms of the disease, CAN10 reduced both pathological inflammation and fibrosis in skin and lung tissue, factors associated with clinical severity in humans. CAN10 also normalized a number of biomarkers closely

    Cantargia presents new data at SITC 2022 supporting nadunolimab’s promising antitumor clinical efficacy

    Data shows nadunolimab dual mechanism potently reduces levels of tumor-promoting molecules Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new data providing further insights to the mechanisms underlying the antitumor activity of the IL1RAP-binding antibody nadunolimab (CAN04). In a model of the pancreatic cancer (PDAC) microenvironment, nadunolimab potently reduced levels of various tumor-promoting molecules, in sharp contrast to an anti-IL-1β antibody which showed no such effects. PDAC and non-small cell lung cancer (NSCLC) patients treated with nadunolimab and

    Invitation to presentation of Cantargia’s report for the third quarter of 2022 on November 10 at 3.00 p.m. CET

    Cantargia AB will publish the company’s report for the third quarter of 2022 on Thursday, November 10, 2022, at 08:30 a.m. CET.In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on November 10, at 3:00 p.m. CET, where Göran Forsberg, CEO, and Bengt Jöndell, CFO, will present Cantargia and comment on the quarterly report for the third quarter 2022, followed by a Q&A-session. The conference call can be followed at: https://tv.streamfabriken.com/cantargia-q3-2022 To attend through telephone, please dial-in at

    Cantargia reaches recruitment milestone and focuses nadunolimab development on upcoming randomized studies

    Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced that the clinical trials CAPAFOUR and CESTAFOUR have enrolled enough patients to halt recruitment. Preliminary results show acceptable safety of the chemotherapy combinations with Cantargia’s lead asset, the IL1RAP-binding antibody nadunolimab (CAN04), as well as signs of efficacy in a cohort of non-small cell lung cancer (NSCLC) patients treated with nadunolimab and gemcitabine/cisplatin in CESTAFOUR. Consequently, clinical development of nadunolimab will focus on planned randomized trials in the lead indications. Additionally,

    Cantargia reports first non-squamous NSCLC patient treated with nadunolimab, Keytruda® and chemotherapy

    Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that the first patient has been treated in a new arm of the phase Ib clinical trial CIRIFOUR. The new arm adds Cantargia’s lead asset, the IL1RAP-binding antibody nadunolimab (CAN04), to the recently established first line therapy for non-small cell lung cancer (NSCLC). Up to 24 non-squamous NSCLC patients will be treated with a combination of nadunolimab, the checkpoint inhibitor Keytruda® (pembrolizumab) and platinum-based chemotherapy. The objective is to assess safety, efficacy, and biomarkers.“We are thrilled to advance

    Cantargia: Oral presentation of new preclinical CAN10 efficacy data in systemic sclerosis at ACR Convergence

    Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data demonstrating efficacy of its anti-inflammatory IL1RAP-binding antibody CAN10 in an additional model of systemic sclerosis. CAN10 alleviated disease manifestations in this model, which is one of the most commonly used models of the disease. These findings will be presented in an oral presentation at the annual rheumatology conference ACR Convergence, held in Philadelphia, November 10-14, 2022.“CAN10 continues to demonstrate promising effects in preclinical models of systemic sclerosis and the new data

    Cantargia presents preclinical data demonstrating unique treatment effects of nadunolimab on pancreatic cancer stromal cells

    Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported preclinical data for its lead candidate, the IL1RAP-binding antibody nadunolimab (CAN04), further supporting the promising clinical efficacy seen in pancreatic cancer (PDAC) patients. The new results show that nadunolimab reduces PDAC tumor growth through a strong impact on cancer-associated fibroblasts (CAF), a major component of tumor-supporting stromal cells within PDAC tumors. Furthermore, the broad and unique mode-of-action of nadunolimab disrupts crosstalk between PDAC cells and CAF in sharp contrast to blockade of IL-1β

    New number of shares and votes in Cantargia

    The number of shares and votes in Cantargia AB (publ) has changed due to the recently completed rights issue (for further information, see the company’s press release on 12 August 2022). Through the rights issue, the number of shares and votes in Cantargia increased by 66,795,158. Today, on the last trading day of the month, there are in total 166,987,895 shares and votes in Cantargia. For further information, please contactGöran Forsberg, CEOTelephone: +46 (0)46-275 62 60E-mail: goran.forsberg@cantargia.com This is information that Cantargia AB is obliged to make public

    Cantargia publishes preclinical data on strong anti-tumor efficacy of nadunolimab in combination with chemotherapy

    Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported publication of preclinical results demonstrating that Cantargia’s lead candidate, the IL1RAP-binding antibody nadunolimab (CAN04), shows synergistic anti-tumor efficacy with chemotherapy through a mechanism likely to be highly relevant in the clinical situation. The effect is dependent on the unique capability of nadunolimab to simultaneously block both the alpha and beta forms of interleukin-1 (IL-1). These findings support the promising clinical interim data observed with nadunolimab in pancreatic cancer (PDAC) and non-small

    Cantargia publishes half year report

    Cantargia AB’s (”Cantargia”) half year report for the period January until June 2022 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the second quarter · At ASCO 2022, one of the world’s largest cancer congresses, Cantargia presented interim clinical data for nadunolimab for the more than 100 patients with pancreatic cancer (PDAC) or non-small cell lung cancer (NSCLC) included in the phase IIa part of the CANFOUR study, and for the first patients in the CIRIFOUR study. · Positive preclinical efficacy data were

    Invitation to presentation of Cantargia’s report for the second quarter of 2022 on August 30 at 3.00 p.m. CET

    Cantargia AB will publish the company’s report for the second quarter for 2022 on Tuesday, August 30, 2022, at 08:30 a.m. CET.In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on August 30, at 3:00 p.m. CET, where Göran Forsberg, CEO, and Bengt Jöndell, CFO, will present Cantargia and comment on the quarterly report for the second quarter 2022, followed by a Q&A-session. The conference call can be followed at: https://tv.streamfabriken.com/cantargia-q2-2022 To attend through telephone, please dial-in at one

    Cantargia announces final outcome of the company’s significantly oversubscribed rights issue

    THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.12 August 2022 – The final outcome in Cantargia AB’s (publ) (“Cantargia” or the “Company”

    Cantargia reports new positive preclinical efficacy data for CAN10 supporting development in myocarditis

    Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data from a collaboration with Johns Hopkins University School of Medicine demonstrating efficacy of CAN10 in a viral myocarditis model. The results highlight the potential of CAN10 in the treatment of this common form of myocarditis ahead of planned clinical trials. The data will be presented in a poster session at one of the world’s largest meetings on innovations in cardiac health, the Basic Cardiovascular Sciences (BCVS) Scientific Sessions 2022, being held in Chicago, July 25-28, 2022.The IL1RAP-binding

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media